NEW YORK
,
Dec. 17, 2020
/PRNewswire/ —
If you own shares in any of the companies listed above and
would like to discuss our investigations or have any questions concerning
this notice or your rights or interests, please contact:
Joshua Rubin, Esq.
WeissLaw LLP
1500 Broadway, 16
th
Floor
New York
, NY 10036
(212) 682-3025
(888) 593-4771
[email protected]
Waddell & Reed Financial, Inc.
(NYSE: WDR)
WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of
Waddell & Reed Financial, Inc. (NYSE: WDR)
in connection with the proposed acquisition of the company by Macquarie Asset Management. Under the terms of the agreement, the company’s shareholders will receive
$25.00
in cash for each share of WDR common stock that they hold. If you own WDR shares and wish to discuss this investigation or your rights, please call us at one of the numbers listed above or visit our website:
https://weisslawllp.com/news/wdr/
Akers Biosciences, Inc.
(NASDAQ: AKER)
WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of
Akers Biosciences, Inc. (NASDAQ: AKER)
in connection with the company’s proposed merger with privately-held MyMD Pharmaceuticals, Inc. (“MyMD”). Under the terms of the merger agreement, AKER and MyMD will combine resulting in current MyMD stockholders owning 80% of the combined post-close company, leaving AKER stockholders with a mere 20% of the new entity. If you own AKER shares and wish to discuss this investigation or your rights, please call us at one of the numbers listed above or visit our website:
https://www.weisslawllp.com/aker/
Cellular Biomedicine Group, Inc.
(NASDAQ: CBMG)
WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of
Cellular Biomedicine Group, Inc. (NASDAQ: CBMG)
in connection with the proposed interested-party acquisition of the company by an entity consisting of CBMG’s CEO
Tony Liu
, members of the company’s management, and a consortium of investors. Under the terms of the agreement, shareholders will receive
$19.75
in cash for each share of CBMG common stock that they own. If you own CBMG shares and wish to discuss this investigation or your rights, please call us at one of the numbers listed above or visit our website:
http://www.weisslawllp.com/cellular-biomedicine-group-inc/
Helix Technologies, Inc.
(OTC: HLIX)
WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of
Helix Technologies, Inc. (OTC: HLIX)
in connection with the proposed stock-for-stock merger of the company with Medical Outcomes Research Analytics, LLC. Under the terms of the agreement, HLIX stockholders will receive 0.02731 shares of a newly formed company, Forian Inc. If you own HLIX shares and wish to discuss this investigation or your rights, please call us at one of the numbers listed above or visit our website:
https://www.weisslawllp.com/hlix/
View original content to download multimedia:
http://www.prnewswire.com/news-releases/shareholder-alert-weisslaw-llp-reminds-wdr-aker-cbmg-and-hlix-shareholders-about-its-ongoing-investigations-301195761.html
SOURCE WeissLaw LLP
